New clinic aims to tackle heart failure and meth addiction at the same time
NCT ID NCT07211724
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This pilot study will test a clinic that treats both heart failure and methamphetamine use disorder together in 50 adults. Patients will receive heart failure medications and addiction counseling, plus incentives for staying meth-free. The goal is to see if this combined approach improves abstinence, medication use, and quality of life over 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Los Angeles General Medical Center
Los Angeles, California, 90089, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Southern California, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Los Angeles, California, 90089, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
behavioral counseling, contingency management, and optional medications (mirtazapine, bupropion, naltrexone)
What this could lead to
If successful, this integrated care model could improve heart failure outcomes and methamphetamine abstinence in a high-risk group, potentially reducing hospitalizations and deaths.
What could go wrong
This is a small pilot study (50 people) with no control group, so results may not be generalizable. The intervention is complex and adherence may be low.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.